Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 5/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991770 | 0.93 | PDK2 (0.48) | PDK2KDM4EALDH1A1KAT6AKAT5 | |
| SCHEMBL12177889 | 0.90 | PDK2 (0.43) | PDK2KDM4EALDH1A1PPARAPPARD | |
| SCHEMBL2479940 | 0.84 | KDM4E (0.44) | THRAKDM4EALDH1A1TDP1APP | |
| SCHEMBL12177881 | 0.81 | PDK2 (0.46) | PDK2KDM4EKAT6AKAT5MMP2 | |
| SCHEMBL991641 | 0.79 | MEN1 (0.36) | PDK2KDM4EPPARAPOLB | |
| SCHEMBL991076 | 0.78 | CYP3A4 (0.41) | PDK2PPARAPPARD | |
| SCHEMBL991359 | 0.78 | GAA (0.48) | PDK2ALDH1A1PPARD | |
| SCHEMBL12925102 | 0.78 | TRPM8 (0.36) | PDK2KDM4EALDH1A1PPARAPPARD | |
| SCHEMBL12177875 | 0.78 | PDK2 (0.41) | PDK2THRAKDM4EALDH1A1KAT6A | |
| SCHEMBL992923 | 0.78 | BCHE (0.35) | PDK2KDM4EPPARAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011140009-A1 | METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | PDK2 1957/4885THRA 3022/4885KDM4E 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.